Screening | Baseline/Enrollment Visit 0 (V0) | Treatment visit 1 (V1) | Follow up visit 2 (V2, week 6) | Follow up visit 3 (V3, week 12) | Follow up visit 4 (V4, week 24) | Follow up visit 5 (V5, week 36) | Follow up visit 6 (V6, week 48) | Follow up visit 7 (V7, week 60) | Follow up visit 8 (V8, week 72) | Follow up visit 9 (V9, week 84) | Follow up visit 10 (V10, week 96) | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Informed consent form | ✓ | |||||||||||
Randomization | ✓ | |||||||||||
Demographics | ✓ | |||||||||||
Medical history | ✓ | |||||||||||
Physical examinationa | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Vital signs | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Performance status | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Concomitant medications | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Hemotologyb | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Serum biochemistryc | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Hepatic disease examinationd | ✓ | ✓ | ||||||||||
Abdominal CT or MRI | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
Whole-body CT scan | ✓ | ✓ | ✓ | ✓ | ||||||||
EKG (as indicated) | ✓ | |||||||||||
Fibrosis evaluation (Acoustic Radiation Force Impulse; ARFI) | ✓ | |||||||||||
Pregnancy test (urine)e | ✓ | |||||||||||
Adverse event evaluation | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |